Company begins commercial shipments of the recently-acquired Sample-to-Result testing platform to U.S. and EMEA Microbiology Labs; APAC placements to commence in the coming weeks
Singapore, November 1, 2018 – Vela Diagnostics today announced it has commenced shipments of the Great Basin diagnostics system to customer sites in the United States and Europe. In preparation for the launch, Vela Diagnostics has re-listed products with FDA and CE-IVD under Vela Diagnostics brand name.
This commercial launch follows Vela’s acquisition of the Great Basin assets in June of this year and adds microbiology capabilities to Vela's existing business in virology and oncology. Initial site placements are evaluating the company’s Stool Bacterial Pathogens Panel, the first assay to be manufactured by Vela post acquisition, and will quickly be followed by the availability of Great Basin’s five additional US-IVD and CE-marked assays, including the Staph ID/R Blood Culture Panel, Group B Strep Test, Shiga Toxin Direct Test, Bordetella Direct Test, and the Toxigenic C. diff Test. All the Great Basin assays utilize the Great Basin Analyzer, an easy-to-use, sample-in/result-out instrument designed to perform automated sample extraction and chip-based detection in a fully-enclosed cartridge with integrated data analysis.
“Our global teams, including the Vela Operations team in Salt Lake City (former Great Basin), have been working diligently on operational integration in order to quickly deliver the valuable Great Basin platform back into microbiology labs for fast, multi-pathogen, near-patient testing,” said Michael Tillmann, CEO of Vela Diagnostics. “We are pleased by the positive response we’ve received from former Great Basin users as well as from Vela’s traditional customer base, and we look forward to growing the menu of near-patient assays on this system that complements Vela’s low-plex PCR and high multiplexing NGS solutions.”
Vela Diagnostics is the only provider of an automated IVD Next–Generation Sequencing (NGS) workflow in the market. Vela’s Real-Time PCR and NGS applications are available on one integrated Sentosa® platform; this provides a unique ability for the customers to leverage one system for two workflows, while carrying out tests for various targets in order to answer current clinical and research questions, as well as drive laboratory operations efficiency. s
More information can be found on Vela’s website at www.veladx.com.